Poll: Do You Agree with the FDA's Decision to Pull Avastin?

Article

This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy.

Everyone wants the best treatment available when it comes to cancer, breast cancer is no different. This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy. Avastin is still available for other types of cancer but because it is no longer approved for breast cancer insurance companies will not cover the approximately $8000.00 per month it costs. This puts breast cancer treatment out of reach for many women who say this was working for them.

Recent Videos
Dr. Somi Javaid highlights disparities in sexual health | Image Credit: hermd.com.
How advancements in IVF are impacting embryologist workload and patient care | Image Credit: fertility.coopersurgical.com/our_experts
Study finds no causal link between maternal health in pregnancy and autism risk | Image Credit: med.nyu.edu/faculty.
Mirvie's RNA platform revolutionizes detection of fetal growth restriction | Image Credit: wexnermedical.osu.edu
How early genetic testing empowers parents and improves outcomes | Image Credit: tuftsmedicine.org
Dallas Reed highlights trends and barriers in prenatal genetic testing | Image Credit: tuftsmedicine.org
How maternal fetal medicine specialists improve outcomes for high-risk pregnancies | Image Credit: profiles.mountsinai.org
How the cobas liat assay panels improve STI detection | Image Credit: labqualityconfab.
Screening-to-diagnosis interval vital for gestational diabetes outcomes | Image Credit: ultracon2024.eventscribe.net
Henri M. Rosenberg, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.